Publication: 2427

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)
      QxMD      Google Scholar   
Citation:
Breast Cancer Res Treat vol 160 (2) 297-304
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
6
Parents:
938   2244   2296  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
40601- GSK 40603- Genentech  
Grants:
P30 CA016672, U10 CA180821, P30 CA008748, U10 CA180818, U10 CA180882, U10 CA180867, U10 CA180838, U10 CA180888  
Corr. Author:
 
Authors:
                           
Networks:
CA043, LAPS-CT018, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-UT003, NY021, RI005   
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-40601, CALGB-40603
Phases:
2, 3
Keywords:
Neoadjuvant therapy, HER2-positive breast cancer, Breast conserving therapy